2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2714 Secondary mature T/NK-cell lymphomas following CD19 CAR-T therapy were observed exclusively among patients with prior alkylator exposure: A real-world EHR analysis

Kausik Maiti, MD, Heidi Cho, MD2, Nancy Lunney VI, MA3, Chris Learn, PhD4
1 Parexel, Raleigh, North Carolina, United States
2 Parexel, Raleigh, North Carolina, United States
3 Parexel, Raleigh, North Carolina, United States
4 Parexel, Raleigh, North Carolina, United States

Background

Secondary mature T/NK-cell malignancies have emerged as a rare but clinically important safety concern following CD19-directed CAR-T therapy. Prior reports have highlighted cumulative treatment burden, including exposure to previous cytotoxic therapies, as a biologically plausible contributor; however, specific pre-treatment susceptibility phenotypes associated with these events remain poorly characterized.

Aims

To evaluate the association between prior alkylating agent exposure and subsequent development of mature T/NK-cell lymphoma following CD19-directed CAR-T therapy.

Methods

A retrospective cohort study was conducted using the TriNetX Global Network (query executed July 2026). Adults with diffuse large B-cell lymphoma treated with axicabtagene ciloleucel, tisagenlecleucel, or brexucabtagene autoleucel were identified. Patients with documented exposure to alkylating agents (including cyclophosphamide, bendamustine, melphalan, busulfan, and related agents) within 3 years before CAR-T infusion were compared with patients without documented alkylator exposure during the same period. The primary outcome was incident mature T/NK-cell lymphoma (ICD-10-CM C84) occurring 1–1825 days after CAR-T infusion, excluding patients with pre-existing outcome diagnoses. Absolute risk differences, Kaplan–Meier analyses, and log-rank tests were performed. A sensitivity analysis was conducted in the TriNetX Dataworks - Global Network using a 31–1825-day risk window. Baseline demographic, treatment, and hematologic characteristics were evaluated for comparability.

Results

A total of 2,660 CAR-T-treated patients met study criteria, including 2,200 patients with documented alkylating agent exposure within the 3 years preceding CAR-T infusion and 460 patients without documented alkylating agent exposure. Median follow-up following CAR-T infusion was 560 days among alkylating agent exposed patients and 376 days among patients without prior alkylating agent exposure. In the primary analysis conducted in the TriNetX Global Network, incident mature T/NK-cell lymphoma events occurring 1–1825 days following CAR-T infusion were evaluated. Thirty incident mature T/NK-cell lymphoma events were observed among alkylating agent exposed patients, whereas no events were observed among patients without prior alkylating agent exposure. The absolute risk difference was 1.4% (95% CI 0.9–1.8%; p=0.012). Kaplan–Meier analysis demonstrated significantly different event-free survival distributions between cohorts (log-rank p=0.028).

Baseline age (64 vs 63 years), sex distribution (62.7% vs 63.8% male), and CAR-T product utilization (axi-cel 80% vs 83%, tisa-cel 17% vs 17%, brexu-cel 4% vs 2%) were broadly similar between cohorts. Baseline neutropenia was more frequent among alkylating agent exposed patients (81% vs 62%).

A sensitivity analysis conducted in the TriNetX Dataworks - Global Network using a more restrictive 31–1825-day risk window demonstrated a concordant directional finding, with all 14 observed incident mature T/NK-cell lymphoma events occurring among alkylating agent exposed patients. Exploratory analyses evaluating prior autologous stem-cell transplantation, lymphodepletion exposure, and propensity-score-matched outcome cohorts were limited by insufficient event counts, precluding stable estimation.

Conclusions

In this large real-world EHR analysis, all observed secondary mature T/NK-cell lymphoma events following CD19-directed CAR-T therapy occurred among patients with documented prior alkylating agent exposure. This previously unrecognized association identifies a potential pre-treatment susceptibility phenotype for a rare but serious post-CAR-T malignancy. If confirmed, these findings could inform risk stratification, treatment planning, and targeted surveillance strategies, enabling a more individualized approach to CAR-T therapy.

Kausik Maiti, MD: No relevant conflicts of interest to declare.